The main purpose of this legislation is to prohibit the use of federal funds for purchasing drugs that are made in China. It aims to encourage the procurement of pharmaceuticals from other countries that meet U.S. health and safety standards. This is part of a broader effort to ensure drug safety and reduce reliance on Chinese manufacturing in the pharmaceutical sector. Key provisions of the law include a phased approach to drug procurement.